drugset / Trial / NCT00465673
Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer
Phase 2
Terminated
2 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
TTY Biopharm · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary objective: To determine the brain response rate of Lipo-Dox in breast cancer patients with brain metastasis Secondary objectives: 1. To determine the overall objective response rate (ORR) 2. To determine the progression free survival, and duration of objective response 3. To evaluate the overall survival (OS) 4. To assess the safety profiles
Timeline
- Start
- 2005-09
- Primary completion
- 2009-07
- Completion
- 2009-07
Outcome
Outcome not reported
Stopped (Enrollment): “Low recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | — |